High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial [Research Articles]

This study suggests that high-throughput genomics could improve outcomes in a subset of patients with hard-to-treat cancers. Although these results are encouraging, only 7% of the successfully screened patients benefited from this approach. Randomized trials are needed to validate this hypothesis and to quantify the magnitude of benefit. Expanding drug access could increase the percentage of patients who benefit. Cancer Discov; 7(6); 586–95. ©2017 AACR.
See related commentary by Schram and Hyman, p. 552.
This article is highlighted in the In This Issue feature, p. 539

Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Authors: Massard, C., Michiels, S., Ferte, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., Ngo-Camus, M., Bahleda, R., Gazzah, A., Varga, A., Postel-Vinay, S., Loriot, Y., Even, C., Breuskin, I., Auger, N., Tags: Research Articles Source Type: research